Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Oncology·MeSH: Neoplasm Metastasis
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| amg 436 | AMGEN INC (AMGN) |
Frequently asked questions
How many drugs are in development for Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)?
BioSniper tracks 1 drug in development for Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) across 1 company.
How many clinical trials target Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)?
There are 1 clinical trial targeting Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) tracked by BioSniper.
Deep-dive into Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis